[A26-09] Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years) – Benefit assessment according to §35a Social Code Book V
Last updated 06.08.2026
Project no.:
A26-09
Commission:
Commission awarded on 05.02.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Treatment of symptomatic, inoperable plexiform neurofibromas in paediatric patients with neurofibromatosis type 1, aged 1 to < 3 years
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-09
| Project no. | Title | Status |
|---|---|---|
| A26-76 | Selumetinib (plexiform neurofibromas in neurofibromatosis type 1, 1 to < 3 years) – Addendum to Project A26-09 | Commission completed |
Federal Joint Committee (G-BA)
06-08-2026 A G-BA decision was published.
G-BA documents on this decision